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ABSTRACT
Objectives We used findings from the Global Burden
of Disease Study 2013 to report the burden of
musculoskeletal disorders in the Eastern Mediterranean
Region (EMR).
Methods The burden of musculoskeletal disorders was
calculated for the EMR’s 22 countries between 1990
and 2013. A systematic analysis was performed on
mortality and morbidity data to estimate prevalence,
death, years of live lost, years lived with disability and
disability-adjusted life years (DALYs).
Results For musculoskeletal disorders, the crude DALYs
rate per 100 000 increased from 1297.1 (95% uncertainty
interval (UI) 924.3–1703.4) in 1990 to 1606.0 (95% UI
1141.2–2130.4) in 2013. During 1990–2013, the total
DALYs of musculoskeletal disorders increased by 105.2%
in the EMR compared with a 58.0% increase in the rest of
the world. The burden of musculoskeletal disorders as a
proportion of total DALYs increased from 2.4% (95% UI
1.7–3.0) in 1990 to 4.7% (95% UI 3.6–5.8) in 2013.
The range of point prevalence (per 1000) among the EMR
countries was 28.2–136.0 for low back pain, 27.3–49.7
for neck pain, 9.7–37.3 for osteoarthritis (OA), 0.6–2.2
for rheumatoid arthritis and 0.1–0.8 for gout. Low back
pain and neck pain had the highest burden in EMR
countries.
Conclusions This study shows a high burden of
musculoskeletal disorders, with a faster increase in
EMR compared with the rest of the world. The
reasons for this faster increase need to be explored.
Our findings call for incorporating prevention and
control programmes that should include improving
health data, addressing risk factors, providing
evidence-based care and community programmes to
increase awareness.
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INTRODUCTION
Musculoskeletal disorders have been underestimated and even
ignored for a long time, mainly due to their low fatality rate
and being viewed as irreversible conditions or simply part of the
ageing process.1 The considerable contribution of musculoskel-
etal disorders is now more clear and several studies have quanti-
en of musculoskeletal disorders.2 They
valent causes of absence from work and
de.2 High frequency, chronicity and
sculoskeletal disorders impose a consid-
on the communities. Population ageing
lly increase the burden of musculoskel-
coming decades.3 Despite these facts,
s have not been a focus of public health
in low-income and middle-income
rranean Region (EMR), epidemiological
disorders are sparse and not easily com-
ata in this region come from baseline
nity Oriented Program for Control of
PCORD). The programme, designed by
ernational League of Associations for
980s, is presumably the most eminent
e to tackle the burden of musculoskel-
ddle-income countries.5 Some countries
Egypt, Iran, Kuwait, Lebanon, Pakistan
ed COPCORD projects in the past two
D baseline surveys have shown a high
keletal conditions in the region; for
l complaints during the past seven days
d 45% of people in Iran, based on four
an areas. The most common anatomical
knees (27%), dorsolumbar spine (24%),
vical spine (14%).7 Lifetime prevalence
lems was reported by around 33% of
a current point prevalence of approxi-
7% of individuals in Kuwait reported
d the most common sites of pain were
rs.9 In the northern part of Pakistan in
e had rheumatic diseases with higher
s (16.5%) compared with poor urban
rban areas (10.7%).10 Musculoskeletal
or disorders) were generally more
ompared with males.8–12 The overall
keletal conditions was higher in rural
areas compared with urban.10 13 Original data from other coun-
tries of the region are usually limited to specific diseases.14–17 In
the demographic and health survey of Palestine, 2% of the
population reported a diagnosis of musculoskeletal diseases,
with an increasing prevalence with age.18 Some of the countries
in the region have no accessible original data on the magnitude
and intensity of musculoskeletal disorders.
There is not a comprehensive summary or comparable data
on the burden of musculoskeletal disorders in the countries of
this region. In this report, which is part of the Global Burden of
Diseases, Injuries, and Risk Factors Study 2013 (GBD 2013), we
present the prevalence and burden of musculoskeletal disorders
(low back pain, neck pain, osteoarthritis, rheumatoid arthritis,
gout and other musculoskeletal disorders) at the regional and
national levels in the EMR from 1990 to 2013, as well as the
attributable burden from the known risk factors of musculoske-
letal disorders.
METHODS
GBD 2013 covers 188 countries, 7 super-regions and 21
regions from 1990 to 2013. In total, 306 causes of diseases and
injuries, 240 causes of death and 79 risk factors were systematic-
ally analysed. Details on the methodology of GBD studies and
the main changes to the methods for GBD 2013 have been
explained in previous publications.2 19–21
There are 22 countries in the EMR by WHO designation
with different levels of Gross National Income per capita. The
low-income countries are Afghanistan, Djibouti, Somalia and
Yemen; middle-income countries: Egypt, Iraq, Iran, Jordan,
Lebanon, Libya, Morocco, Pakistan, Palestine, Sudan, Syria and
Tunisia; and high-income countries: Bahrain, Saudi Arabia,
Kuwait, Oman, Qatar and the United Arab Emirates.
In GBD 2013, the burden from six main categories of muscu-
loskeletal disorders was calculated: rheumatoid arthritis, osteo-
arthritis, low back pain, neck pain, gout and other
musculoskeletal disorders. We used the International Statistical
Classification of Diseases and Related Health Problems, tenth
revision (ICD-10) codes or their equivalent codes in the earlier
versions of ICD and assumed different sequelae for each dis-
order (table 1). Each musculoskeletal disorder had a list of
sequelae with potentially different levels of disability; for
instance, low back pain had eight sequelae classified as mild,
moderate, severe and most severe low back pain with or
without leg pain. Range of disability weight for these sequelae
was different from 0.02 (95% uncertainty interval (UI) 0.011–
disorders, equivalent ICD-10 codes and list of sequelae for each disorder in the Global Burden of Disease Study
0 codes Sequelae (number of sequelae)
M06.9, M08.0-M08.89 Mild, moderate and severe rheumatoid arthritis (3)
M13.9, M15-M19.079 Mild, moderate, and severe osteoarthritis of the hip; mild, moderate
and severe osteoarthritis of the knee (6)
, G54.3, G54.4, G57.0-G57.12, M43.2-M43.5, M43.8, M43.9, M45-M49,
-M49.89, M51-M51.9, M53, M53.2-M54, M54.1-M54.18, M54.3-M54.9,
M99.1-M99.9
Mild, moderate, severe and most severe low back pain without leg
pain; mild, moderate, severe and most severe low back pain with
leg pain (8)
, M50-M50.93, M53.0, M53.1, M54.0-M54.09, M54.2 Mild, moderate, severe and most severe neck pain (4)
M10.19, M10.3-M10.9 Asymptomatic gout, symptomatic episodes of gout and
polyarticular gout (3)
L93-L93.2, M00-M03.0, M03.2, M03.6, M07-M08, M08.9-M09.0,
, M09.8, M11-M12, M12.2- M12.49, M12.8-M12.9, M14-M14.89,
M25.879, M30-M32.9, M34-M36.8, M40-M43.19, M65-M68.8,
M73, M73.8, M75-M77.9, M80-M83.4, M83.8-M87.09, M87.3-M89.59,
-M95.9, M99.0-M99.09.
Asymptomatic other musculoskeletal disorders and other
musculoskeletal disorders severity levels 1–6 (7)
Classification of Diseases and Related Health Problems, tenth revision.
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0.035) for mild low back pain without leg pain to 0.384 (95%
UI 0.256–0.518) for most severe low back pain with leg pain. A
complete list of health state descriptions and equivalent disabil-
ity weights is available in the web appendix of a previous GBD
publication.21
In this study, the burden is described as prevalence, deaths,
due to premature mortality, years lived
d disability-adjusted life-years (DALYs).
age-standardised rates to be able to dis-
n population structure from the differ-
sex-specific rates.
loskeletal disorder categories (except
the category of ‘other musculoskeletal
d to be non-fatal with no mortality and
ture mortality. To estimate the cause-
mortality envelopes (total number of
were estimated for each country during
3. All accessible data from vital registra-
story surveys, sample registration data
deaths were considered for preparing
of death data was extracted from the
s any available verbal autopsies.19 We
nsemble modelling 22 to estimate the
heumatoid arthritis and ‘other musculo-
, sex, country and year.
, we updated the GBD 2010 systematic
ical measures for each musculoskeletal
ent strategies to avoid missing sources of
ring of the results of systematic reviews
ork of GBD collaborators.21 A list of
ns is available on the Global Health
tp://ghdx.healthdata.org/gbd-2013-data-
yesian meta-regression analyses through
sed for disease modelling. We used fixed
and country-level covariates to adjust
le of study-level covariates, we included
OA disease definition as the reference
extracted data from other studies that
porting having had a diagnosis of OA’,
of OA regardless of symptoms’ or ‘OA
adiographic confirmation’. More details
le in the online appendix of a previous
sed epidemiological estimates in com-
weights were used to calculate cause-
age, sex, location and calendar year.21
hrough summation of YLLs and YLDs.
able burden of the following risk factors
of musculoskeletal disorders: occupa-
, high body mass index and low glom-
tails on definitions of these risk factors
r musculoskeletal disorders are available
previous publication.20
% UIs for each quantity in this analysis.
king 1000 samples of posterior distribu-
and 975th values of the distribution.21
ue to musculoskeletal disorders in EMR
5% UI 1380–2090) in 1990 to 5084
9) in 2013, a 198% increase.
rate was 0.89 per 100 000 (95% UI
1.39 per 100 000 (95% UI 1.07–1.58)
of deaths in 2013 was equal to 0.83
0 (95% UI 0.62–0.95) and constitutes
0.14% (95% UI 0.10–0.16) of all deaths. YLLs of musculoskel-
etal disorders increased from 68 211 (95% UI 52 961–86 586)
in 1990 to 183 659 (95% UI 131 166–219 907) in 2013, a
169% increase.
Web appendix table S1 shows point prevalence of musculo-
skeletal disorders in the EMR countries. Low back pain was the
most common condition in all countries in 2013, except Kuwait
and Lebanon where neck pain was more prevalent: the range of
point prevalence of low back pain was between 32.45 per 1000
in Kuwait and 159.23 in Egypt. The range of point prevalence
of neck pain was between 34.31 per 1000 in Pakistan and >55
per 1000 in Somalia and Djibouti. Osteoarthritis ranged from
29.67 per 1000 in Pakistan to >46 per 1000 in Somalia and
Djibouti. Point prevalence of gout had a range of 0.15 per 1000
in Pakistan to 1.00 per 1000 in Iran and Qatar. Point prevalence
of rheumatoid arthritis was between 0.88 per 1000 in Saudi
Arabia and >3 per 1000 in Somalia and Djibouti (web
appendix table 1). YLDs of musculoskeletal disorders increased
from 1279 per 100 000 (95% UI 907–1686) in 1990 to 1576
(95% UI 1111–2100) in 2013. Musculoskeletal disorders were
the second leading cause of YLDs after ‘mental and substance
use disorders’ and accounted for 15.7% of all YLDs (95% UI
13.8–17.7%) in 2013. Low back pain and neck pain had the
highest YLDs among the disorders (web appendix 1).
As expected, YLDs were the main component of DALYs for
musculoskeletal disorders (>98%, both in 1990 and 2013), and
DALY estimates were very close to YLD estimates. The total
burden of musculoskeletal disorders was 4 842 603 DALYs
(95% UI 3 450 654–6 359 159) in 1990 and increased to
9 946 874 DALYs (95% UI 7 068 174–13 194 791) in 2013, a
105.4% increase in total DALYs of musculoskeletal disorders,
compared with a 58.0% increase in the rest of the world. The
crude DALYs rate per 100 000 increased from 1297.1 (95% UI
924.3–1703.4) in 1990 to 1606.0 (95% UI 1141.2–2130.4) in
2013, which shows a 23.8% increase. Age-standardised DALY
rates were 2055.6 (95% UI 1478.3–2704.1) in 1990 and
increased by 2.9% to 2115.9 (95% UI 1517.2–2799.7) in 2013.
The burden of musculoskeletal disorders as a proportion of
total DALYs has constantly increased since 1990; the proportion
that was 2.4% (95% UI 1.7–3.0) in 1990 increased to 3.2%
(95% UI 2.8–4.6) in 2000 and 4.7% (95% UI 3.6–5.8) in 2013.
Figure 1 compares the burden of musculoskeletal disorders in
the EMR to data for the world, low/middle-income countries
and high-income countries. Table 2 summarises DALY rates for
each musculoskeletal disorder. As shown, DALY rates have been
increased during 1990–2013 for all musculoskeletal disorders,
both in men and women.
Egypt had the highest and Lebanon had the lowest
age-standardised musculoskeletal disorders DALY rates both for
males and females. Ranges of age-standardised DALY rates had a
considerable overlap between the low-income, middle-income
and high-income countries of EMR (table 3).
DALY rates had a clear increasing pattern with age; however,
those of middle age had the highest number of DALYs (figure 2).
Among different musculoskeletal disorders, low back pain had
the highest proportion of DALYs in all age groups. The propor-
tion of osteoarthritis DALYs out of total DALYs of musculoskel-
etal disorders increased with age. In individuals aged ≥65 years,
osteoarthritis was the second important cause of DALYs after
low back pain.
The burden of musculoskeletal disorders was higher in
females compared with males, except for low back pain and
gout. The total burden was 5 415 756 DALYs (95% UI 3 877
474–7 150 503) in females and 4 531 118 DALYs (95% UI 3
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males in 2013. DALY rates were 1800.9
) and 1422.2 (95% UI 1004.5–1891.6)
spectively. Figure 3 shows the burden of
order by sex in 2013. Gout had a small
LYs per 100 000 in women and men,
en has not been shown in the figure.
The ratio of age-standardised female to male musculoskeletal
DALY rates ranged between 1.02 in Morocco and 2.01 in Iran
(table 3). The ratio of age-standardised female to male DALY
rates was <1 for gout disease in all countries of the region.
For low back pain, the ratio was <1 except for Sudan (1.02),
Egypt (1.03), Saudi Arabia (1.15), Lebanon (1.43) and Iran
uloskeletal disorders in the Eastern Mediterranean Region compared with the world, high-income countries and
. DALYs, disability-adjusted life-years.
isability-adjusted life-years (per 100 000) for musculoskeletal disorders in the Eastern Mediterranean Region, 1990 and
Year
Both Male Female
Rate 95% UI Rate 95% UI Rate 95% UI
1990 733.6 497.0–1001.2 770.7 519.2–1059.0 694.6 475.0–959.1
2013 870.6 583.9–1197.9 911.5 612.8–1268.1 827.3 561.2–1148.7
1990 280.5 194.4–386.6 226.0 156.5–310.0 337.8 235.6–467.5
2013 351.8 244.5–483.2 274.2 190.2–376.6 434.0 302.8–592.4
1990 103.8 72.8–140.0 74.9 52.5–101.7 134.2 94.4–181.0
2013 131.7 92.2–179.0 93.9 65.4–127.1 171.8 120.3–233.9
1990 33.7 25.4–43.1 25.7 19.3–32.5 42.0 31.1–54.3
2013 37.6 28.4–48.2 30.3 22.8–38.8 45.2 33.8–58.4
1990 0.9 0.6–1.2 1.3 0.9–1.8 0.5 0.3–0.6
2013 1.2 0.8–1.6 1.7 1.2–2.3 0.6 0.4–0.8
1990 144.7 99.5–200.0 76.6 54.9–104.3 216.3 145.3–303.9
2013 213.2 151.3–292.2 110.6 80.2–152.8 322.1 224.1–445.2
1990 1297.2 924.3–1703.4 1175.3 821.4–1558.4 1425.4 1024.4–1.879.6
2013 1606.0 1141.2–2130.4 1422.2 1004.5–1891.6 1800.9 1289.4–2377.7
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ve-mentioned cases, for each country
ge-standardised female to male DALY
mic factors and high body mass index
t risk factors for musculoskeletal disor-
(95% UI 1 023 600–2 148 137) DALYs
were attributable to occupational ergo-
66 DALYs (95% UI 283 614–626 896)
tributable to high body mass index.
ALYs (95% UI 313 110–642 108) of
re attributable to high body mass index.
c factors were the most important risk
h body mass index was a more import-
he attributable burden to occupational
3.2 times of the attributable burden to
n men and 0.8 for women. This ratio
3 in the low-income countries of the
iddle-income countries and 0.8–1.5 in
es of the region.
evalence and burden of musculoskeletal
low back pain, neck pain and osteoarth-
burden of these disorders has increased
he rest of the world during 1990–2013.
burden is mainly related to increase in
ing, despite most of the other diseases,
n the age-standardised rates of burden.
The proportion of musculoskeletal disorders’ burden over total
burden of disease has even increased. Musculoskeletal disorders
are the second leading cause of disability in the EMR. Although
population ageing is a main reason for increasing burden of
musculoskeletal disorders, a large proportion of the burden is
imposed on people in their most active and productive years of
life. We did not find a specific association between income level
of the country and burden of musculoskeletal disorders;
however, the relative importance of risk factors (occupational
ergonomic factors compared with high body mass index) was
different based on the income level of countries.
Our findings call for incorporating prevention and control
programmes for musculoskeletal disorders in national health
programmes. COPCORD could be used as a stepwise approach
to address the high burden of musculoskeletal disorders;
however, previous COPCORD programmes in EMR usually
have not progressed beyond the early stages (such as baseline
surveys) towards a focus on prevention and control activities.6 23
Considering the important risk factors of musculoskeletal disor-
ders, public education, occupational health and safety and ergo-
nomics are among the most important components of any
prevention and control programme. Medical interventions and
rehabilitation to preserve functional status are essential to
provide control of the situation.
Advocacy is required to raise the attention of policy and deci-
sion makers to the disease burden caused by musculoskeletal
disorders.3 As a reflection on the previous round of the ongoing
GBD study, some experts recommended extensive involvement
Table 3 Age-standardised disability-adjusted life year rates (per 100 000) of musculoskeletal disorders by country and sex in the Eastern
Mediterranean Region, 2013
Both Male Female
F/M ratioCountries Rate 95% UI Rate 95% UI Rate 95% UI
Low-income countries
2125 1507–2800 1864 1293–2500 2362 1630–3189 1.27
2075 1497–2743 1819 1280–2456 2312 1638–3130 1.27
2020 1463–2621 1880 1350–2473 2151 1522–2835 1.14
1998 1429–2643 1856 1307–2448 2122 1527–2826 1.14
2848 1989–3863 2459 1692–3335 3201 2256–4309 1.3
2370 1708–3153 2034 1442–2715 2683 1936–3529 1.32
2352 1683–3108 2318 1650–3123 2370 1692–3114 1.02
2322 1664–3056 1539 1084–2026 3095 2216–4090 2.01
2274 1605–3003 2028 1418–2718 2507 1770–3348 1.24
2195 1555–2972 1943 1318–2692 2450 1713–3340 1.26
2177 1533–2925 1862 1209–2593 2480 1745–3285 1.33
2040 1438–2728 1880 1289–2590 2165 1531–2905 1.15
2007 1389–2732 1849 1240–2579 2161 1479–2990 1.17
1992 1413–2654 1842 1307–2450 2125 1511–2803 1.15
1636 1186–2158 1603 1156–2140 1670 1205–2197 1.04
1287 937–1715 1093 792–1450 1500 1077–2004 1.37
2205 1598–2914 1994 1404–2686 2505 1765–3376 1.26
2161 1528–2852 1806 1247–2404 2650 1837–3558 1.47
2080 1470–2782 1825 1222–2538 2436 1718–3259 1.33
2078 1485–2764 1914 1318–2587 2499 1788–3323 1.31
2040 1463–2688 1985 1400–2651 2151 1535–2840 1.08
1361 983–1794 1126 809–1469 1741 1254–2298 1.55
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to initiate any intervention for control
ders and integrating services with exist-
res.3 Mody and Brooks suggested new
egies to train community health workers
providers to detect and initiate the man-
rlier stages.24
ients and the entire population, treat-
interventions, prevention through iden-
of environmental and genetic risks are
f interventions after primary epidemio-
People with musculoskeletal conditions
m of services including traditional, com-
ve therapies of which efficacies may not
nt biological medications and surgical
the long-term outcomes of some mus-
uch as rheumatoid arthritis or severe
they can be too expensive to be afford-
imely access to healthcare providers is
f the musculoskeletal disorders. For
with inflammatory disorders such as
rly assessment by a specialist improves
ver, previous studies show that many
oskeletal disorders do not receive treat-
in Lebanon, around a quarter of these
ind of treatment.26 On the other hand,
using unnecessary diagnostic or thera-
eople with musculoskeletal symptoms,
er countries. This needs to be avoided
for quaternary prevention.
le factors (such as maintaining physical
, having a balanced diet, avoidance of
lcohol consumption, and preventing
injuries) is not only beneficial for musculoskeletal health but
also for other non-communicable diseases that contribute to
increasing mortality and morbidity.24
Low back pain and neck pain have the highest burden of mus-
culoskeletal disorders in most of the EMR countries. In previous
studies, the seven-day period prevalence of pain for dorsolum-
bar and cervical spine in Iran were 23.7% and 14.2%, respect-
ively.7 The estimates were higher in rural areas compared with
urban areas, and also in people with specific jobs and pregnant
women.29 In Kuwait, the point prevalence of low back pain in
schoolchildren aged 10–18 years old was 20.6% in males and
39.3% in females.30 A cumulative prevalence of around 28%
for low back pain was reported by children aged 11–19 years
old in Tunisia.31 Some of these estimates cannot be directly
compared with our estimates due to different definitions and
the time interval used for assessment. However, the available
evidence collectively reflects the importance of the problem.
There are several evidence-based public health and clinical
guidelines for low back pain32–34 and neck pain,35 36 usually
from high-income countries. Development of suitable guidelines
for use in resource-poor settings is challenging. Most research
evidence originates from high-income countries and may not be
relevant or applicable to the needs of low-income countries.
Moreover, the development of valid clinical guidelines needs
resources and certain expertise that sometimes is not available.
In the paucity of nationally developed guidelines, EMR coun-
tries can use the available guidelines through adaptation
processes.37
Osteoarthritis is an important cause of disability, especially in
elderly people. It is expected to be influenced by the population
ageing process more than other musculoskeletal disorders. Some
evidence suggests that intensive physical activity might increase
es and numbers of disability-adjusted life-years (DALYs) of musculoskeletal disorders in the Eastern Mediterranean
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large joints; however, this is not a
dings on association of physical activity
pecially confusing in the elderly; while
at walking and physical exercise has a
eoarthritis, there are some reviews that
n elder individuals can help to reduce
arthritis.39 Light or moderate physical
known to increase risk or complications
l activity can also decrease risk of osteo-
g body mass index.38 39 The burden of
disorders’ was around threefold in
men. Conditions such as fibromyalgia
disorders are more prevalent among
mitations. Although we estimated a col-
culoskeletal disorders in this study, we
e estimations for some of the disorders
and systemic connective tissue disor-
not separately assess the burden of hand
sification of musculoskeletal disorders
ion between symptoms, complaints and
10 codes clarify the components of each
clude osteoporosis as a disease; instead,
y was classified as a risk factor for frac-
e burden has not been shown in this
t provide separate estimates for diseases
such as the Behçet disease, which have regional importance in
EMR or individual (but not collective) high burden.
There were issues with availability and quality of data in some
EMR countries; however, we used GBD modelling approaches
to reduce this issue. Indeed, the lack of high-quality data in the
region, especially from the 1990s, might have an influence on
the estimated trend of musculoskeletal diseases. Although this
issue exists for many of the causes of diseases, it might have an
imbalanced effect on musculoskeletal diseases (the importance
of which has been highlighted in the recent decades) compared
with the other diseases. This factor might affect different regions
of the world in different ways. However, we do not believe that
it can purely explain the faster increase in burden of musculo-
skeletal disorders in EMR compared with the rest of the world.
CONCLUSION
Findings from this study show a high burden of musculoskeletal
disorders, especially low back pain, neck pain and osteoarthritis
in the region. The reasons for faster increase of musculoskeletal
disorders’ burden in EMR during 1990–2013 compared with
the rest of the world need to be explored. Our findings call for
integrating prevention and control programmes for musculoskel-
etal disorders with health system programmes. Plans should
include improving health data to monitor trends, addressing
known risk factors especially through health education and
awareness, ergonomics and occupational health and safety, and
usculoskeletal disorders in the Eastern Mediterranean Region by sex, 2013. DALYs, disability-adjusted life-years.
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providing evidence-based early diagnosis and treatment,
rehabilitative care and community programmes to increase
knowledge of risk and protective factors.
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